Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inuvo, Inc.INUV · Entity 7934 | Director | June 30, 2018 | July 03, 2018 |
| ORAGENICS INCOGEN · Entity 8495 | Director | December 11, 2025 | December 15, 2025 |
| Scienture Holdings, Inc.MEDS · Entity 7802 | Director | September 01, 2022 | September 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inuvo, Inc.
Report date June 30, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2019-03-31 | Direct | 38,961 |
Reported balance
After 2018-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-30 · Grant · Acquired 38,961 · Balance 38,961 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's Common Stock.
ORAGENICS INC
Report date December 11, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Director Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-12-11 | Direct | 125,000 |
Reported balance
After 2025-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 125,000 · Balance 125,000 F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.
Scienture Holdings, Inc.
Report date September 01, 2022 · Filed September 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 65,437 |
Reported balance
After 2022-09-01 transaction · row 1
1 source rowRow 1 · 2022-09-01 · Grant · Acquired 54,525 · Balance 65,437 F1: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on the grant date, September 1, 2022, and 1/4th of such shares on each of October 1, 2022, January 1, 2023 and April 1, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on the grant date, September 1, 2022, and 1/4th of such shares on each of October 1, 2022, January 1, 2023 and April 1, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).
F2: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2025 Filed Dec 15, 2025 16:12 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001136354-25-000002 · primary_doc.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-12-11 F1 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 21:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-24-037732 · ownership.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-09-19 F1 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 16:30 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-027581 · ownership.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,471 F1 · shares: Represents an award of restricted stock pursuant to the Company's non-employee director compensation program under the Company's 2021 Equity Incentive Plan with 20,000 shares vesting immediately and 5,000 shares vesting in six (6) months. F2 · balance_after: Reflects adjustments made in connection with the 1-for-60 reverse stock split of the Issuer's common stock which became effective on January 23, 2023. Read SEC document |
| September 01, 2022 Filed Sep 16, 2022 16:59 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 54,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-026091 · ownership.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,437 F1 · shares: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on the grant date, September 1, 2022, and 1/4th of such shares on each of October 1, 2022, January 1, 2023 and April 1, 2023, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 16:40 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001493152-22-021021 · ownership.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2032-07-29 F1 · security: Represents an award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2021 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, July 29, 2022. F1 · shares: Represents an award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2021 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, July 29, 2022. F1 · derivative.underlying_shares: Represents an award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2021 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, July 29, 2022. F1 · balance_after: Represents an award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2021 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, July 29, 2022. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 17:11 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001493152-21-031895 · ownership.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-16 F1 · security: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · derivative.underlying_shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · balance_after: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. Read SEC document |
| May 27, 2021 Filed Jun 2, 2021 16:50 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 10,912 | $3.78 | $41,247.36 |
DisclosureSEC source: 0001493152-21-013442 · ownership.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,912 F1 · shares: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/3 of the shares on October 1, 2021 and January 1 and April 1, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2 · balance_after: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 16:35 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001493152-21-004419 · ownership.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-02-18 F1 · security: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · derivative.underlying_shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · balance_after: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:18 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 156,540 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-20-001783 · ownership.xml · derivative · entry 2 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,540 Underlying: Common Stock · 156,540 shares Expires 2030-02-05 F2 · security: Represents a discretionary retention award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's Plan. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · shares: Represents a discretionary retention award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's Plan. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · derivative.underlying_shares: Represents a discretionary retention award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's Plan. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · balance_after: Represents a discretionary retention award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's Plan. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:18 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 156,540 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-20-001783 · ownership.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,540 Underlying: Common Stock · 156,540 shares Expires 2030-02-05 F1 · security: Represents an annual award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · shares: Represents an annual award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · derivative.underlying_shares: Represents an annual award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · balance_after: Represents an annual award of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 17:05 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 156,540 | Not disclosed Strike: $0.48 | Not disclosed |
DisclosureSEC source: 0000899243-19-017956 · doc4.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,540 Underlying: Common Stock · 156,540 shares Expires 2029-06-20 F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. F1 · price: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. F1 · derivative.underlying_shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a non-employee director. The option exercise price is the closing price on the date of the grant, June 20, 2019 (the "Grant Date"). The options vest quarterly in even amounts over the four quarters following the Grant Date. Read SEC document |
| September 27, 2018 Filed Oct 1, 2018 16:32 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000899243-18-025663 · doc4.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-09-27 F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended in connection with service to the Company as a director. The options vest immediately. The option exercise price is the closing price on the date of the grant, September 27, 2018. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended in connection with service to the Company as a director. The options vest immediately. The option exercise price is the closing price on the date of the grant, September 27, 2018. Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 21:02 UTC | Inuvo, Inc. INUV · Entity 7934 | GrantRestricted Stock Unit · Derivative | 38,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-011352 · doc4.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,961 Underlying: Common Stock · 38,961 shares Expires 2019-03-31 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 16:47 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0000899243-18-018154 · doc4.xml · derivative · entry 2 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-06-22 F2 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a director. The options vest one year from the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2018. F2 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a director. The options vest one year from the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2018. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 16:47 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018154 · doc4.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,108 F1 · shares: Represents an award of restricted stock in connection with service to the Company as a director pursuant to the 2012 Equity Incentive Plan that vests immediately. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 21:27 UTC | Inuvo, Inc. INUV · Entity 7934 | Exercise / conversionRestricted Stock Unit · Derivative | 23,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-007210 · doc4.xml · derivative · entry 2 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,256 shares Expires 2018-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 21:27 UTC | Inuvo, Inc. INUV · Entity 7934 | Exercise / conversionCommon Stock | 23,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-007210 · doc4.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 15:28 UTC | ORAGENICS INC OGEN.BC · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000899243-17-017199 · doc4.xml · derivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2027-06-22 F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a director. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2017 F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan in connection with service to the Company as a director. The options vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2017 Read SEC document |
| April 01, 2017 Filed Apr 5, 2017 00:00 UTC | Inuvo, Inc. INUV · Entity 7934 | GrantRestricted Stock Unit · Derivative | 23,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-007565 · doc4.xml · derivative · entry 3 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,256 Underlying: Common Stock · 23,256 shares Expires 2018-03-31 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| March 31, 2017 Filed Apr 5, 2017 00:00 UTC | Inuvo, Inc. INUV · Entity 7934 | Exercise / conversionRestricted Stock Unit · Derivative | 15,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-007565 · doc4.xml · derivative · entry 2 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,790 shares Expires 2017-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| March 31, 2017 Filed Apr 5, 2017 00:00 UTC | Inuvo, Inc. INUV · Entity 7934 | Exercise / conversionCommon Stock | 15,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-007565 · doc4.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 16:07 UTC | ORAGENICS INC OGEN.BC · Entity 8495 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003782 · doc4.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,063 F1 · shares: Represents an award of restricted stock in connection with service to the Company as a director pursuant to the 2012 Equity Incentive Plan that vests equally over each of the four calendar quarters during 2017. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:59 UTC | Inuvo, Inc. INUV · Entity 7934 | PurchaseCommon Stock | 1,000 | $1.11 | $1,110.00 |
DisclosureSEC source: 0001225208-16-041206 · doc4.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,258 Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 21:38 UTC | Inuvo, Inc. INUV · Entity 7934 | Exercise / conversionRestricted Stock Unit · Derivative | 4,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-040419 · doc4.xml · derivative · entry 2 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,667 shares Expires 2016-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's Common Stock. F2 · derivative.exercise_date: The restricted stock units become vested 33.33% per year beginning on the first anniversary of the date of grant. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 21:38 UTC | Inuvo, Inc. INUV · Entity 7934 | Exercise / conversionCommon Stock | 4,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-040419 · doc4.xml · nonDerivative · entry 1 POPE CHARLES L · CIK 0001136354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.